Forest Laboratories

Forest Laboratories develops, manufactures, and markets medicines to the patients who are suffering from diseases in the central nervous system, women's health, gastroenterology,urology, cardiovascular, respiratory, and anti-infective therapeutic categories.

The company's products include Bystolic, which is used to lower heart rate and myocardial contractility; Daliresp, which is used to lower the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treating irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treating moderate to severe dementia.

The company was acquired by Actavis.